
Below is effectiveness information for meningococcal vaccines licensed in the U.S. Click on each vaccine below to learn more.
In general, it is important to understand that the FDA approval of the below vaccines was based on non-inferior safety and immunogenicity profiles. In layman’s terms this means that the vaccine under licensure consideration is no worse than another already licensed. FDA approval of Menactra, the first conjugate vaccine, was made on the basis of non-inferiority against an existing polysaccharide vaccine no longer in use (Menomune). Subsequent FDA approvals of later vaccines have continued to be scaffolded on non-inferior standards largely due to “ethical concerns” of a placebo group not having access to vaccines.
Similar to meningococcal conjugate vaccines, meningococcal serogroup B (MenB) vaccines received FDA approval based on blood tests indicating immune response (immunogenicity) to the particular strains found within the vaccine. Meningococcal serogroup B strains, however, are quite diverse, and as a result, vaccine effectiveness is difficult to assess. Additionally, serogroup B disease rates were at historical lows and disease outbreaks sporadic prior to the licensing of MenB vaccines may limit the ability to determine effectiveness. See additional information below for MenB vaccines.